Lu Peng 4

What Happened
Lu Peng, Chief Medical Officer of Pharvaris N.V., exercised stock options and immediately sold the resulting 14,166 shares on May 1, 2026. The option exercise acquired 14,166 shares at $2.59 per share (total cost $36,690). The shares were sold in two transactions — 14,023 shares at a weighted-average price of $30.16 (proceeds $422,986) and 143 shares at $31.00 (proceeds $4,433) — for total gross sale proceeds of approximately $427,419. Net proceeds after the exercise cost were roughly $390,729. This was an option exercise followed by sales, not an open-market purchase.

Key Details

• Transaction date: May 1, 2026; Form 4 filed May 5, 2026.
• Option exercise: 14,166 shares acquired @ $2.59, total $36,690.
• Sales: 14,023 shares @ $30.16 (weighted average) = $422,986; 143 shares @ $31.00 = $4,433. Total sales ≈ $427,419.
• Footnotes: sales were scheduled under a Rule 10b5-1 trading plan (F1); the sales were in connection with a cashless exercise of options (F3). Report notes sale prices ranged $30.00–$30.99 and the filer can provide per-price breakdown on request. Vesting history for the options is included (25% vested Feb 3, 2021, remainder monthly thereafter) (F2).
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Filing timeliness: Form lists transaction date and filing date; no late-filing flag shown in the provided excerpt.

Context

• This was an exercise of vested options followed by immediate sale (a cashless exercise under a pre-set 10b5-1 plan), a common way for insiders to monetize option gains. Such transactions are generally considered routine and executed pursuant to a pre-established plan rather than a real-time trading decision.